



PRESS RELEASE

FOR RELEASE: TUESDAY, NOVEMBER 9, 6:30 AM EST

Aperion Biologics, Inc. Receives Therapeutic Discovery Project Grant

AN ANTONIO, TX — Aperion Biologics, Inc. (ABI), an orthobiologics company focused on regenerative medicine with a technology platform which provides unique solution to the global surgical need for human based grafts from an alternative source of tissue announced that the Company has received a grant totaling nearly \$250,000 under the Qualifying Therapeutic Discovery Project.

Daniel Lee, CEO of ABI, commented, “We are thrilled to be a recipient of the grant under the Qualifying Therapeutic Discovery Project Program. The grant affords us additional means to continue the development of our scaffold that can both function and deliver a therapeutic agent as it remodels. This represents a new paradigm in ACL reconstruction with faster return of function which is less invasive and more cost effective.”

About the Qualifying Therapeutic Discovery Project

The Qualifying Therapeutic Discovery Project tax credit was enacted as part of the Patient Protection and Affordable Care Act of 2010. The benefit is targeted to therapeutic discovery projects that show potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions. In addition, the Qualifying Therapeutic Discovery Project credit was made available to small and mid-sized biotech, pharmaceutical and medical device companies with up to a 50% tax credit for investments in qualified therapeutic discoveries for tax years 2009 and 2010, or a grant for the same amount tax-free. Allocation of the credit also took into consideration which projects show the greatest potential to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in life, biological and medical sciences.

About Aperion Biologics, Inc.

ABI, located in San Antonio, Texas, is a clinical-stage medical device company addressing the need for alternatives to human-based grafts with patented animal based tissue. Aperion Biologics, Inc. has developed and patented a technique to make animal tissues usable for human applications without causing rejection. The core platform technology is an enzymatic stripping of the key carbohydrate antigens followed by a unique conversion process that both “humanizes” and sterilizes the tissues without affecting their biomechanical or biological properties. This tissue scaffold provides mechanical stability and function while being biologically integrated and remodeled. Aperion’s Z-Process™ of humanizing and sterilizing tissue can be applicable to a variety of tissues from orthopedic ligaments, bone, and meniscus to cardiovascular valves and vessels to soft tissue grafts for augmentation and repair.

For more information, please contact:

Daniel R. Lee

Chief Executive Officer

Aperion Biologics, Inc.

Phone: 210.858.7070

dlee@aperionbiologics.com

www.aperionbiologics.com